Neuroprotective peptides
AssigneeThe University of Western Australia
InventorBruno Meloni
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.
Claims21
1-30. (canceled)
An isolated peptide for the treatment or prevention of neural injury, said isolated peptide comprising 10 to 32 amino acid residues in length, wherein the isolated peptide includes at least 10 to 22 arginine residues.
An isolated polynucleotide sequence encoding a peptide for the treatment or prevention of neural injury, said polynucleotide sequence comprising:
- a codon sequence coding for a 10 to 32 amino acid peptide having at least 10 to 22 arginine residues,
- a complementary sequence that is complementary to the codon sequence,
- a hybridization sequence that hybridizes under stringent conditions with the codon sequence, and
- a homology sequence having at least 60% homology with the codon sequence,
- wherein the isolated polynucleotide sequence is a non-naturally occurring polynucleotide, a man-made artificial construct, cDNA, or a vector including the isolated nucleic acids.
A pharmaceutical composition for the treatment or prevention of a neural injury, for promoting survival of neurons and/or for inhibiting cell death, the pharmaceutical composition or medicament including a peptide of 10 to 32 amino acid residues, wherein the peptide comprises at least 10 to 22 arginine residues.
Dependencies are inferred from the claim text.